219 related articles for article (PubMed ID: 21196168)
21. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
Hamzaoui L; El Bouchtili S; Siai K; Mahmoudi M; Azzouz MM
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):e16-20. PubMed ID: 22959099
[TBL] [Abstract][Full Text] [Related]
23. Response predictors to treatment with pegylated interferon in chronic hepatitis B.
Ferreira PR; Tenore Sde B
Braz J Infect Dis; 2010; 14(5):519-25. PubMed ID: 21221484
[TBL] [Abstract][Full Text] [Related]
24. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.
Freedman ND; Curto TM; Lindsay KL; Wright EC; Sinha R; Everhart JE;
Gastroenterology; 2011 Jun; 140(7):1961-9. PubMed ID: 21376050
[TBL] [Abstract][Full Text] [Related]
25. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
26. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
Veldt BJ; Heathcote EJ; Wedemeyer H; Reichen J; Hofmann WP; Zeuzem S; Manns MP; Hansen BE; Schalm SW; Janssen HL
Ann Intern Med; 2007 Nov; 147(10):677-84. PubMed ID: 18025443
[TBL] [Abstract][Full Text] [Related]
27. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
28. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
[TBL] [Abstract][Full Text] [Related]
29. [Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].
Zhu F; Zhang QY; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):173-174. PubMed ID: 29807402
[TBL] [Abstract][Full Text] [Related]
30. [Therapy of hepatitis C].
Moradpour D; Blum HE
Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options.
Alfaiate D; Dény P; Durantel D
Antiviral Res; 2015 Oct; 122():112-29. PubMed ID: 26275800
[TBL] [Abstract][Full Text] [Related]
32. Chronic hepatitis delta: A state-of-the-art review and new therapies.
Gilman C; Heller T; Koh C
World J Gastroenterol; 2019 Aug; 25(32):4580-4597. PubMed ID: 31528088
[TBL] [Abstract][Full Text] [Related]
33. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
Saitta C; Pontisso P; Brunetto MR; Fargion S; Gaeta GB; Niro GA; Picciotto A; Smedile A; Squadrito G; Raimondo G
Antivir Ther; 2006; 11(7):931-4. PubMed ID: 17302256
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic viruses and hepatocellular carcinoma.
Ben Ari Z; Weitzman E; Safran M
Clin Liver Dis; 2015 May; 19(2):341-60. PubMed ID: 25921667
[TBL] [Abstract][Full Text] [Related]
35. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
[TBL] [Abstract][Full Text] [Related]
36. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
37. Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
Morgan TR; Ghany MG; Kim HY; Snow KK; Shiffman ML; De Santo JL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Dienstag JL; Morishima C; Lindsay KL; Lok AS;
Hepatology; 2010 Sep; 52(3):833-44. PubMed ID: 20564351
[TBL] [Abstract][Full Text] [Related]
38. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
[TBL] [Abstract][Full Text] [Related]
39. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
40. HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh C; Da BL; Glenn JS
Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
